NFIL3 and metabolic dysfunction-associated steatohepatitis: Given that liver‐targeted E4BP4 antagonists may be fraught with side effects including impaired liver NK cell and innate immunity, inhibition of the signal‐driven E4BP4‐YAP interaction might hold great potential in curbing over‐activation of hepatocyte E4BP4 in MASH patients without affecting the normal physiological actions of E4BP4.